Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Debt to Equity (2020 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Debt to Equity for 8 consecutive years, with $0.4 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 73.31% year-over-year to $0.4, compared with a TTM value of $0.4 through Dec 2025, down 73.31%, and an annual FY2025 reading of $0.4, down 73.31% over the prior year.
  • Debt to Equity was $0.4 for Q4 2025 at Zevra Therapeutics, down from $0.46 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.8 in Q2 2024 and bottomed at -$1.16 in Q2 2022.
  • Average Debt to Equity over 5 years is $0.53, with a median of $0.46 recorded in 2025.
  • The sharpest move saw Debt to Equity skyrocketed 923.86% in 2024, then crashed 73.31% in 2025.
  • Year by year, Debt to Equity stood at $0.01 in 2021, then skyrocketed by 1738.14% to $0.17 in 2022, then surged by 305.7% to $0.69 in 2023, then soared by 117.0% to $1.5 in 2024, then tumbled by 73.31% to $0.4 in 2025.
  • Business Quant data shows Debt to Equity for ZVRA at $0.4 in Q4 2025, $0.46 in Q3 2025, and $0.52 in Q2 2025.